Literature DB >> 25233965

Chromosomal abnormalities in primary myelodysplastic syndrome.

Anila Rashid1, Mohammad Khurshid2, Usman Shaikh1, Salman Adil1.   

Abstract

OBJECTIVE: To determine the frequency of cytogenetic abnormalities in patients diagnosed as primary myelodysplastic syndrome (MDS) using conventional karyotyping. STUDY
DESIGN: Case series. PLACE AND DURATION OF STUDY: The Clinical Laboratory, The Aga Khan University Hospital, Karachi, between January 2006 - June 2012.
METHODOLOGY: Patients of all ages and either gender who fulfilled WHO criteria for MDS were included. Cytogenetic analysis was conducted at the time of diagnosis. Patients who had secondary MDS were excluded from analysis. Chromosome identification and karyotype description was done according to the International System for Chromosome Nomenclature (ISCN, 1995) and described as frequency percentage.
RESULTS: Out of the 122 cases of MDS, 71 patients had their karyotype done at the time of diagnosis, including 42 males (59.2%) and 29 females (40.8%) with median age of 60 years. Forty one (57.7%) showed normal karyotype and 30 (42.3%) showed clonal karyotypic abnormalities at diagnosis. Out of which 14 (19.7%) had single, 11 (15.5%) had complex and 6 (8.5%) had double cytogenetic abnormalities. The common abnormalities found were: trisomy 8 in 7 cases (9.9%), -7/del (7q) in 3 cases (4.2%), -Y and complex 5q in 2 cases (2.8%) each, complex trisomy 8, del 11q , inversion 9, trisomy 19 and del 20q were found in 1 case (1.4%) each. Other abnormalities were found in 11 cases (15.5%).
CONCLUSION: Trisomy 8 was the most common disorder/abnormality found in this study population followed by the complex cytogenetics.

Entities:  

Mesh:

Year:  2014        PMID: 25233965     DOI: 09.2014/JCPSP.632635

Source DB:  PubMed          Journal:  J Coll Physicians Surg Pak        ISSN: 1022-386X            Impact factor:   0.711


  8 in total

1.  Clinico-Hematological and cytogenetic spectrum of adult myelodysplastic syndrome: The first retrospective cross-sectional study in Iranian patients.

Authors:  Mostafa Paridar; Kazem Zibara; Seyed Esmaeil Ahmadi; Abbas Khosravi; Maral Soleymani; Ebrahim Azizi; Omid Kiani Ghalesardi
Journal:  Mol Cytogenet       Date:  2021-05-08       Impact factor: 2.009

2.  Clinicohematological and cytogenetic profile of myelodysplastic syndromes in Pakistan-compare and contrast.

Authors:  Nida Anwar; Aisha Arshad; Muhammad Nadeem; Sana Khurram; Naveena Fatima; Sumaira Sharif; Saira Shan; Tahir Shamsi
Journal:  Mol Cytogenet       Date:  2017-05-08       Impact factor: 2.009

3.  Myelodysplastic Syndrome in Pakistan: Clinicohematological Characteristics, Cytogenetic Profile, and Risk Stratification.

Authors:  Rafia Mahmood; Chaudry Altaf; Parvez Ahmed; Saleem Ahmed Khan; Hamid Saeed Malik
Journal:  Turk J Haematol       Date:  2017-06-07       Impact factor: 1.831

4.  Comprehensive analysis of genetic factors predicting overall survival in Myelodysplastic syndromes.

Authors:  Nehakumari Maurya; Purvi Mohanty; Somprakash Dhangar; Purvi Panchal; Farah Jijina; S Leo Prince Mathan; Chandrakala Shanmukhaiah; Manisha Madkaikar; Babu Rao Vundinti
Journal:  Sci Rep       Date:  2022-04-08       Impact factor: 4.379

5.  Cytogenetic characteristics in Vietnamese patients diagnosed with primary myelodysplastic syndromes.

Authors:  Minh Phuong Vu; Hong Quang Ha; Cuc Nhung Nguyen
Journal:  Leuk Res Rep       Date:  2022-08-12

6.  Environmental and occupational determinants of myelodysplastic syndrome: A case-control study from Pakistan.

Authors:  Nida Anwar; Aisha Arshad; Naveena Fatima; Sumaira Shaheen; Sumera Bukhari; Tahir Shamsi
Journal:  Cancer Rep (Hoboken)       Date:  2021-10-27

7.  Phenotypic and Cytogenetic Characterization of Mesenchymal Stromal Cells in De Novo Myelodysplastic Syndromes.

Authors:  A J I S Rathnayake; H W W Goonasekera; V H W Dissanayake
Journal:  Anal Cell Pathol (Amst)       Date:  2016-08-29       Impact factor: 2.916

8.  Cytogenetic features in primary myelodysplastic syndrome Egyptian patients.

Authors:  Yasser Elnahass; Lamiaa Youssif
Journal:  J Adv Res       Date:  2018-02-07       Impact factor: 10.479

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.